Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide can cause hair loss in some people, though it is not listed as a common side effect in the medicine's licensed information. When it does happen, the likely culprit is not the drug itself but a well-understood biological response to rapid weight loss called telogen effluvium — a temporary shedding that typically settles within a few months. That said, if you are noticing thinning and you are on semaglutide, the feeling of uncertainty is real and worth taking seriously. This page sets out what the clinical evidence shows, the factors that make hair shedding more or less likely, and when it is worth raising with a prescriber. Semaglutide (sold as Wegovy in the UK for weight management) is a prescription-only medicine; any concerns about side effects are best discussed as part of an ongoing clinical review rather than managed alone. The NHS medicines page for semaglutide covers the recognised side-effect profile in full.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most clinicians who look carefully at this question land in the same place: semaglutide does not directly attack hair follicles. What it does do, very effectively, is reduce appetite and accelerate weight loss, and losing a significant amount of weight quickly is a well-established trigger for telogen effluvium. In this condition, a larger-than-usual proportion of hairs shift simultaneously into the resting (telogen) phase and then shed, typically two to four months after the physiological stress that triggered it. So if you started semaglutide in January and noticed shedding in April, the timing fits this pattern almost exactly.
The reason this matters is practical. If telogen effluvium is the mechanism, the intervention is different from what you would do for a drug side effect. Slowing the pace of weight loss, prioritising protein intake, and keeping micronutrients (iron and vitamin D in particular) within normal range all address the actual driver. Stopping semaglutide would also slow weight loss, which might help, but it removes the therapeutic benefit along with it. That is a clinical trade-off worth discussing with your prescriber rather than making unilaterally. You can read more about the broader pattern of semaglutide and hair loss including what the reported rates look like across different studies.
The honest caveat: a direct pharmacological contribution from semaglutide itself cannot be completely ruled out. Post-marketing data are still accumulating. The Mounjaro and Wegovy SmPCs on the eMC list alopecia under uncommon or not-yet-classified events rather than common ones, which gives a rough sense of frequency without being definitive. That is where the evidence sits right now.
Not everyone who takes semaglutide loses noticeable hair. Several factors seem to tilt the odds. Faster weight loss (particularly losing more than roughly half a kilogram per week for an extended period) appears to raise the risk of telogen effluvium regardless of what is causing the calorie deficit. People who were already borderline for iron, ferritin or vitamin D before starting treatment are more vulnerable. Those eating very low amounts of protein while appetite is suppressed may also find their hair more affected, because protein is the primary building block of the hair shaft.
Sex and hormonal background matter too. Hair loss in women on Wegovy tends to attract more attention partly because female-pattern hair thinning is already more prevalent and more socially visible, and partly because hormonal fluctuations (perimenopause, thyroid changes) can compound the picture. None of this makes the experience less valid; it just means unpicking the cause requires a proper clinical history. A question our prescribers hear regularly is whether women on HRT or hormonal contraception are at higher risk, the short answer is that there is no strong evidence for that specifically, though the interactions between these medicines and semaglutide absorption are worth flagging during any review. You can explore specific questions about Wegovy and hair loss in females for a closer look at that angle.
The positive signal, consistently, is that telogen effluvium is self-limiting. Hair usually begins to recover within three to six months once weight stabilises or nutritional gaps are addressed. Regrowth, though sometimes slow, does happen.
Most hair shedding on semaglutide does not need urgent medical attention, but some presentations do. Contact a GP or your prescribing team promptly if: hair loss is sudden or patchy rather than a diffuse general thinning; you notice bald patches or areas of scalp inflammation; shedding is accompanied by other new symptoms such as fatigue, cold intolerance or rapid heart rate, which might point to a thyroid issue; or the loss feels severe enough to affect your wellbeing significantly.
It is also worth a check-up if you have not had bloods done recently, ferritin levels in particular often sit in the low-normal range that standard panels do not flag, but which is enough to slow hair regrowth. Asking for a ferritin, full blood count and thyroid function test is reasonable and any GP can arrange it.
If you believe semaglutide has contributed directly to hair loss, you can report it as a suspected side effect through the MHRA's Yellow Card scheme. This is exactly the kind of post-marketing signal that helps regulators build a clearer picture over time. It takes a few minutes and is open to patients as well as healthcare professionals.
For a fuller account of Wegovy's side-effect profile beyond hair, including the gastrointestinal effects that affect more people than shedding does, that page covers the full licensed picture. If you are considering starting treatment and want to weigh up the full picture first, our treatment consultation page is the starting point, a real prescriber reads every application and side effects are part of what the consultation covers.
The practical steps are more useful than most people expect, and none of them require stopping treatment. First, audit your protein. On a suppressed appetite it is easy to eat far too little, aim for at least 1.2–1.6 g per kilogram of body weight daily, which usually means deliberately including protein at every meal even when you are not particularly hungry. Second, get your ferritin and vitamin D checked and supplement if either is low. Third, keep your prescriber informed: if your dose is being increased and hair shedding worsens, slowing the titration schedule is a legitimate clinical option.
Some people find topical treatments like minoxidil helpful as a short-term bridge, but that sits outside our prescribing scope and is worth raising with a GP or dermatologist. The main thing to know is that semaglutide-associated hair loss is rarely permanent. The broader semaglutide and hair loss evidence page covers what trial data and post-marketing reports show in more detail.
If you are still deciding whether Wegovy is right for you, our weight-loss treatment overview gives a grounded comparison of options. Speak to our prescribers as part of your free consultation, discussing your medical history, including any previous hair loss, helps them tailor the recommendation to you rather than a template.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.